

Jakob Begun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/122915/publications.pdf>

Version: 2024-02-01

86
papers

5,971
citations

147801

31
h-index

79698

73
g-index

93
all docs

93
docs citations

93
times ranked

9328
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. <i>Intestinal Research</i> , 2023, 21, 161-167.	2.6	1
2	Higher Anti-tumor Necrosis Factor- α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1306-1314.	4.4	19
3	Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 554-580.	1.3	43
4	Inhibition of the master regulator of <i>Listeria monocytogenes</i> virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. <i>PLoS Pathogens</i> , 2022, 18, e1010166.	4.7	7
5	Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis. , 2022, 1, 359-374.		1
6	Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000853.	2.7	9
7	Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 700-704.	3.7	17
8	Secreted NF- κ B suppressive microbial metabolites modulate gut inflammation. <i>Cell Reports</i> , 2022, 39, 110646.	6.4	22
9	Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naïve patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. <i>Lancet, The</i> , 2022, 399, 2200-2211.	13.7	94
10	Psychosocial burden of inflammatory bowel disease in adolescents and young adults. <i>Internal Medicine Journal</i> , 2021, 51, 2027-2033.	0.8	10
11	A Nucleotide Analog Prevents Colitis-Associated Cancer via Beta-Catenin Independently of Inflammation and Autophagy. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 33-53.	4.5	12
12	One-pot Synthesis of pH-Responsive Eudragit-Mesoporous Silica Nanocomposites Enable Colonic Delivery of Glucocorticoids for the Treatment of Inflammatory Bowel Disease. <i>Advanced Therapeutics</i> , 2021, 4, 2000165.	3.2	26
13	Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. <i>Medical Journal of Australia</i> , 2021, 214, 128-133.	1.7	14
14	IgM and IgA augmented autoantibody signatures improve early-stage detection of colorectal cancer prior to nodal and distant spread. <i>Clinical and Translational Immunology</i> , 2021, 10, e1330.	3.8	13
15	Gut microbiota shape the inflammatory response in mice with an epithelial defect. <i>Gut Microbes</i> , 2021, 13, 1-18.	9.8	11
16	Expression of CD49f defines subsets of human regulatory T cells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity. <i>Clinical and Translational Immunology</i> , 2021, 10, e1334.	3.8	5
17	Adhesion to E-selectin primes macrophages for activation through AKT and mTOR. <i>Immunology and Cell Biology</i> , 2021, 99, 622-639.	2.3	2
18	Interferon Lambda Protects Gastrointestinal Stem Cells from Acute Gvhd. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S78.	1.2	0

#	ARTICLE	IF	CITATIONS
19	So many therapiesâ€”So little data: How to choose? Session two summary. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 14-15.	2.8	0
20	IFN-Î» therapy prevents severe gastrointestinal graft-versus-host disease. Blood, 2021, 138, 722-737.	1.4	21
21	pH â€” Responsive colloidal carriers assembled from Î²-lactoglobulin and Epsilon poly-L-lysine for oral drug delivery. Journal of Colloid and Interface Science, 2021, 589, 45-55.	9.4	31
22	Prospective randomised controlled trial of adults with perianal fistulising Crohnâ€™s disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ Open, 2021, 11, e043921.	1.9	4
23	SARSâ€”CoVâ€”2 vaccination in patients with inflammatory bowel disease. GastroHep, 2021, 3, 212-228.	0.6	7
24	Mindfulness based cognitive therapy for youth with inflammatory bowel disease and depression - Findings from a pilot randomised controlled trial. Journal of Psychosomatic Research, 2021, 149, 110594.	2.6	14
25	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50,502 1,430	9.1	1,430
26	Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 873-886.	3.7	43
27	Facile synthesis of dendrimer like mesoporous silica nanoparticles to enhance targeted delivery of interleukin-22. Biomaterials Science, 2021, 9, 7402-7411.	5.4	4
28	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian Journal of Gastroenterology, 2021, , 1-8.	1.5	6
29	Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on diseaseâ€”related knowledge. JGH Open, 2020, 4, 267-272.	1.6	28
30	Malnutrition and quality of life among adult inflammatory bowel disease patients. JGH Open, 2020, 4, 454-460.	1.6	23
31	Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Alimentary Pharmacology and Therapeutics, 2020, 52, 1551-1562.	3.7	38
32	Practical management of inflammatory bowel disease patients during the COVID â€”19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. Internal Medicine Journal, 2020, 50, 798-804.	0.8	12
33	Mindfulness-based cognitive therapy experiences in youth with inflammatory bowel disease and depression: findings from a mixed methods qualitative study. BMJ Open, 2020, 10, e041140.	1.9	7
34	Crohnâ€™s Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2020, 55, 1419-1426.	1.5	11
35	The future of faecal microbiota transplantation in gastrointestinal illness. Microbiology Australia, 2020, 41, 70.	0.4	0
36	Aeromedical retrievals for gastrointestinal disorders in rural and remote Australia: the need for improved access to specialist advice. Internal Medicine Journal, 2020, 50, 619-623.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2020, 69, 801-810.	12.1	52
38	Monitoring Inflammatory Bowel Disease in Pregnancy Using Gastrointestinal Ultrasonography. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1405-1412.	1.3	35
39	Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. <i>World Journal of Gastroenterology</i> , 2020, 26, 4428-4441.	3.3	16
40	MUC13 promotes the development of colitis-associated colorectal tumors via β -catenin activity. <i>Oncogene</i> , 2019, 38, 7294-7310.	5.9	28
41	Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis. <i>Medical Journal of Australia</i> , 2019, 211, 461-467.	1.7	18
42	Distinct Tissue-Specific Roles for the Disease-Associated Autophagy Genes ATG16L2 and ATG16L1. <i>Journal of Immunology</i> , 2019, 203, 1820-1829.	0.8	18
43	MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. <i>Immunity</i> , 2019, 51, 885-898.e7.	14.3	164
44	Protocol for a pilot randomised controlled trial of mindfulness-based cognitive therapy in youth with inflammatory bowel disease and depression. <i>BMJ Open</i> , 2019, 9, e025568.	1.9	9
45	Interleukin-22: friend or foe?. <i>Immunology and Cell Biology</i> , 2019, 97, 355-357.	2.3	2
46	Clinical decision support improves quality of care in patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1040-1051.	3.7	16
47	Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones. <i>Gastroenterology</i> , 2019, 156, 11-14.	1.3	27
48	A systematic review and meta-analysis of mindfulness based interventions and yoga in inflammatory bowel disease. <i>Journal of Psychosomatic Research</i> , 2019, 116, 44-53.	2.6	51
49	Mindfulness-Based Cognitive Therapy Experiences in Youth With Inflammatory Bowel Disease and Depression: Protocol for a Mixed Methods Qualitative Study. <i>JMIR Research Protocols</i> , 2019, 8, e14432.	1.0	5
50	Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. <i>Gut</i> , 2018, 67, 973-985.	12.1	116
51	The role of IL-22 in the resolution of sterile and nonsterile inflammation. <i>Clinical and Translational Immunology</i> , 2018, 7, e1017.	3.8	31
52	Colonic thioguanine pro-drug: Investigation of microbiome and novel host metabolism. <i>Gut Microbes</i> , 2018, 9, 175-178.	9.8	11
53	Selectively targeting the gut in inflammatory bowel disease: Session four summary. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 25-25.	2.8	0
54	Letter: vedolizumab drug concentrations in neonates following intrauterine exposure. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1328-1330.	3.7	14

#	ARTICLE	IF	CITATIONS
55	Positioning biologics—A case-based discussion: Ustekinumab. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 16-17.	2.8	0
56	Personalizing inflammatory bowel disease treatment symposium: Foreward. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 3-3.	2.8	0
57	Predictors in inflammatory bowel disease: Looking into the magic ball: Session one summary. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 4-4.	2.8	0
58	<i>Enterococcus faecalis</i> AHG0090 is a Genetically Tractable Bacterium and Produces a Secreted Peptidic Bioactive that Suppresses Nuclear Factor Kappa B Activation in Human Gut Epithelial Cells. <i>Frontiers in Immunology</i> , 2018, 9, 790.	4.8	15
59	Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism. <i>Gut</i> , 2017, 66, 59-69.	12.1	65
60	The gut bacterium and pathobiont <i>Bacteroides vulgatus</i> activates NF- κ B in a human gut epithelial cell line in a strain and growth phase dependent manner. <i>Anaerobe</i> , 2017, 47, 209-217.	2.1	55
61	Cancer therapeutics with epigallocatechin-3-gallate encapsulated in biopolymeric nanoparticles. <i>International Journal of Pharmaceutics</i> , 2017, 518, 220-227.	5.2	46
62	Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1037-1053.	3.7	225
63	The role of barrier function, autophagy, and cytokines in maintaining intestinal homeostasis. <i>Seminars in Cell and Developmental Biology</i> , 2017, 61, 51-59.	5.0	45
64	Inflammatory bowel disease in the clinic: Escalation and de-escalation of therapy: A longitudinal case-based discussion. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 12-13.	2.8	2
65	High Fat Diets Induce Colonic Epithelial Cell Stress and Inflammation that is Reversed by IL-22. <i>Scientific Reports</i> , 2016, 6, 28990.	3.3	243
66	Genetic Coding Variant in GPR65 Alters Lysosomal pH and Links Lysosomal Dysfunction with Colitis Risk. <i>Immunity</i> , 2016, 44, 1392-1405.	14.3	106
67	Towards an integrated understanding of the therapeutic utility of exclusive enteral nutrition in the treatment of Crohn's disease. <i>Food and Function</i> , 2016, 7, 1741-1751.	4.6	16
68	Integrated Genomics of Crohn's Disease Risk Variant Identifies a Role for CLEC12A in Antibacterial Autophagy. <i>Cell Reports</i> , 2015, 11, 1905-1918.	6.4	45
69	Enteroliths in a Kock continent ileostomy: case report and review of the literature. <i>Endoscopy</i> , 2015, 47, E200-E201.	1.8	4
70	IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3526-3531.	7.1	273
71	Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis. <i>PLoS Genetics</i> , 2013, 9, e1003723.	3.5	185
72	Autophagy at the crossroads of metabolism and cellular defense. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 588-596.	2.3	10

#	ARTICLE	IF	CITATIONS
73	ATG16L1 T300A Dependent Differential Gene Expression Identifies Genes Required for Anti-Bacterial Autophagy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S103.	1.9	0
74	The LRR and RING Domain Protein LRSAM1 Is an E3 Ligase Crucial for Ubiquitin-Dependent Autophagy of Intracellular Salmonella Typhimurium. <i>Cell Host and Microbe</i> , 2012, 12, 778-790.	11.0	202
75	DAF-16-Dependent Suppression of Immunity During Reproduction in <i>Caenorhabditis elegans</i> . <i>Genetics</i> , 2008, 178, 903-918.	2.9	90
76	Staphylococcal Biofilm Exopolysaccharide Protects against <i>Caenorhabditis elegans</i> Immune Defenses. <i>PLoS Pathogens</i> , 2007, 3, e57.	4.7	146
77	<i>Staphylococcus aureus</i> Virulence Factors Identified by Using a High-Throughput <i>Caenorhabditis elegans</i> -Killing Model. <i>Infection and Immunity</i> , 2005, 73, 872-877.	2.2	77
78	The worm has turned "microbial virulence modeled in <i>Caenorhabditis elegans</i> . <i>Trends in Microbiology</i> , 2005, 13, 119-127.	7.7	266
79	<i>Caenorhabditis elegans</i> as a Model Host for <i>Staphylococcus aureus</i> Pathogenesis. <i>Infection and Immunity</i> , 2003, 71, 2208-2217.	2.2	290
80	Long-Lived <i>C. elegans daf-2</i> Mutants Are Resistant to Bacterial Pathogens. <i>Science</i> , 2003, 300, 1921-1921.	12.6	528
81	Crystallization of PNMT, the adrenaline-synthesizing enzyme, is critically dependent on a high protein concentration. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2002, 58, 314-315.	2.5	6
82	Crystal structure of an Xrcc4-DNA ligase IV complex. <i>Nature Structural Biology</i> , 2001, 8, 1015-1019.	9.7	229
83	Getting the Adrenaline Going. <i>Structure</i> , 2001, 9, 977-985.	3.3	60
84	Molecular Recognition of Macrocyclic Peptidomimetic Inhibitors by HIV-1 Protease. <i>Biochemistry</i> , 1999, 38, 7978-7988.	2.5	56
85	Crystallization and preliminary X-ray analysis of thiaminase I from <i>Bacillus thiaminolyticus</i> : space group change upon freezing of crystals. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 1998, 54, 448-450.	2.5	8
86	Substrate-Based Cyclic Peptidomimetics of Phe-Ile-Val That Inhibit HIV-1 Protease Using a Novel Enzyme-Binding Mode. <i>Journal of the American Chemical Society</i> , 1996, 118, 3375-3379.	13.7	77